BPC February 07 update

VTVT data due Monday pre-market; Salarius SLRX and Tonix TNXP offerings

Price and Volume Movers

vTv Therapeutics Inc. (Nasdaq: VTVT) announced that it will release top-line data from Part 2 of the Phase 2 Simplici-T1 trial evaluating TTP399 as an oral adjunctive therapy to insulin in adults with Type 1 diabetes (T1D) on Monday, February 10 at 7:00am ET. Shares are trading up 33% after hours to $2.80.

Moderna, Inc. (NASDAQ: MRNA) shares closed up 17% to $23.24, jumping towards the end of the session following an update at a White House news conference that no glitches have been seen in the development of Moderna's coronavirus vaccine and a human Phase 1 clinical trial will commence within 2.5 months assuming current progress continues.

Assertio Therapeutics, Inc (NASDAQ:ASRT) shares closed Friday up 46% to $1.52 following news released after hours Thursday that Collegium Pharmaceutical, Inc. (NASDAQ: COLL) will acquire its Nucynta franchise of products for $375m in cash. Collegium shares closed Friday up 25% to $25.45.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares slid a further 39% to $0.53, for a running two-day loss of 69%. The company announced Friday an underwritten public offering of shares and warrants for gross proceeds of $7.5m. The offering follows news released late-Wednesday that its Phase 3 posttraumatic stress disorder (PTSD) trial has been terminated due to futility.

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) also announced an underwritten public offering of shares and attached warrants for gross proceeds of approximately $9.6m. Shares slumped to close down 58% to $0.83.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced a 1-for-15 reverse stock split has taken effect and will trade on a split-adjusted basis on February 10, 2020. Shares closed Friday down 19% to $0.28.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Benitec Biopharma Limited (BNTC): $7.44; +39%.

Satsuma Pharmaceuticals, Inc. (STSA): $30.69; +32%.

NeuroBo Pharmaceuticals, Inc. (NRBO): $12.79; +17%.

Aduro BioTech, Inc. (ADRO): $2.87; +14%.

Catalyst Biosciences, Inc. (CBIO): $8.51; +13%.

DECLINERS:

Zogenix, Inc. (ZGNX): $32.12; -39%.

ADMA Biologics, Inc. (ADMA): $3.31; -17%.

PDS Biotechnology Corporation (PDSB): $2.28; -14%.

OncoSec Medical Incorporated (ONCS): $1.86; -13%

Applied Genetic Technologies Corporation (AGTC): $5.00; -12%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ABBV – AbbVie Inc.
Risankizumab MOTIVATE
Crohn’s Disease

Phase 3 Phase 3 data due 2020.
$137.7 billion

ABBV – AbbVie Inc.
Risankizumab KEEPSAKE2
Psoriatic Arthritis

Phase 3 Phase 3 data due 2020.
$137.7 billion

ABBV – AbbVie Inc.
Risankizumab vs secukinumab
Psoriasis

Phase 3 Phase 3 data due 2020.
$137.7 billion

ABBV – AbbVie Inc.
Upadacitinib
Atopic dermatitis

Phase 3 Phase 3 data due 2020.
$137.7 billion

ABBV – AbbVie Inc.
Venclexta (VIALE-A)
Acute Myeloid Leukemia (AML)

Phase 3 Phase 3 data due 2020.
$137.7 billion

ABBV – AbbVie Inc.
Imbruvica + Venclexta (CAPTIVATE)
Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Phase 2 Phase 2 data due 2020.
$137.7 billion

ABBV – AbbVie Inc.
ABBV-951
Parkinson's disease

Phase 3 Phase 3 data due 2021.
$137.7 billion

CBIO – Catalyst Biosciences Inc.
Dalcinonacog alfa – DalcA
Hemophilia B

Phase 2b Phase 2b final data due 2Q 2020.
$76.7 million

MRNA – Moderna Inc.
mRNA vaccine
Coronavirus vaccine

Phase 1 Phase 1 trial to commence by end of April, 2020.
$6.3 billion

VTVT – vTv Therapeutics Inc.
TTP399
Type 1 Diabetes

Phase 1/2 Phase 2 Part 2 data met primary endpoint - February 10, 2020.
$228.8 million